Phase II trial of vorinostat (suberoylanilide hydroxamic acid or SAHA; Zolinza) in combination with gemtuzumab ozogamicin (Mylotarg) as induction and post-remission therapy in older patients with previously untreated non-M3 acute myeloid leukemia.

Trial Profile

Phase II trial of vorinostat (suberoylanilide hydroxamic acid or SAHA; Zolinza) in combination with gemtuzumab ozogamicin (Mylotarg) as induction and post-remission therapy in older patients with previously untreated non-M3 acute myeloid leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2011

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Vorinostat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top